FDA approves biosimilar ogivri for breast, stomach cancers

December 4, 2017

(HealthDay)—Ogivri (trastuzumab-dkst) has been approved by the U.S. Food and Drug Administration as the nation's first biosimilar drug to treat certain breast and stomach cancers, the agency said Friday in a news release.

The maker of a biosimilar must demonstrate that the new product is highly similar to an already approved medication, and that it has no clinically significant difference in terms of its potency, safety, and purity, the FDA said.

Ogivri is approved to treat breast and gastric or gastroesophageal junction adenocarcinoma cancers attributed to human epidermal growth factor receptor 2. The FDA said its maker, Mylan, provided sufficient evidence that the drug is biosimilar to the Genentech drug Herceptin, which was approved by the agency in 1998.

Expected side effects for Ogivri include headache, diarrhea, nausea, chills, fever, infection, , insomnia, cough, and rash, the FDA said. Like Herceptin, Ogivri's label will include a boxed warning about an increased risk of heart disease, serious allergic-like reactions, lung damage, and harm to a developing fetus, the agency said.

Mylan is based in Canonsburg, Penn.

Explore further: FDA approves first biosimilar drug for cancer

More information: More Information

Related Stories

FDA approves first biosimilar drug for cancer

September 15, 2017
(HealthDay)—The first biosimilar drug to treat cancer has been approved by the U.S. Food and Drug Administration.

Zelboraf approved for use in Erdheim-Chester disease

November 8, 2017
(HealthDay)—Zelboraf (vemurafenib) has been approved by the U.S. Food and Drug Administration as the first drug to treat certain adults patients with Erdheim-Chester disease (ECD).

FDA approves first biosimilar drug in US

March 8, 2015
(HealthDay)—The U.S. Food and Drug Administration has approved Zarxio (filgrastim-sndz), the first biosimilar product approved in the United States.

New drug approved for all cancers with genetic marker

May 24, 2017
(HealthDay)—Keytruda (pembrolizumab) has been approved by the U.S. Food and Drug Administration to treat any cancer that has a certain genetic biomarker, regardless of where in the body the cancer originated.

Cheaper breast cancer drug does well in clinical trial

June 3, 2016
(HealthDay)—For women with advanced HER2-positive breast cancer, a similar but less expensive experimental drug works just as well as the standard drug Herceptin (trastuzumab), a new study finds.

Perjeta approved for advanced breast cancer

June 11, 2012
(HealthDay) -- Perjeta (pertuzumab) has been approved by the U.S. Food and Drug Administration to treat people with HER2-positive late-stage breast cancer, the agency said in a news release.

Recommended for you

Complex inhalers prevent patients from taking medicine

February 23, 2018
Respiratory disease patients with arthritis could struggle to manage their conditions because their inhalers are too fiddly for them to use, University of Bath research has found.

Opioid abuse leads to heroin use and a hepatitis C epidemic, researcher says

February 22, 2018
Heroin is worse than other drugs because people inject it much sooner, potentially resulting in increased risk of injection-related epidemics such as hepatitis C and HIV, a Keck School of Medicine of USC study shows.

Opioid addiction treatment behind bars reduced post-incarceration overdose deaths in RI

February 14, 2018
A treatment program for opioid addiction launched by the Rhode Island Department of Corrections was associated with a significant drop in post-incarceration drug overdose deaths and contributed to an overall drop in overdose ...

Heroin vaccine blocks lethal overdose

February 14, 2018
Scientists at The Scripps Research Institute (TSRI) have achieved a major milestone toward designing a safe and effective vaccine to both treat heroin addiction and block lethal overdose of the drug. Their research, published ...

Study shows NIH spent >$100 billion on basic science for new medicines

February 12, 2018
Federally funded research contributed to the science underlying all new medicines approved by the FDA over the past six years, according to a new study by Bentley University.

Opioid use increases risk of serious infections

February 12, 2018
Opioid users have a significantly increased risk of infections severe enough to require treatment at the hospital, such as pneumonia and meningitis, as compared to people who don't use opioids.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.